Efficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety disorder: A 12-week, double-blind, placebo-controlled study

European Neuropsychopharmacology

Volumn 27, Issue 5, 2017, Pages 526-537

  Stein, Dan J ^a   Ahokas, Antti ^b   Jarema, Marek ^c   Avedisova, Alla S ^d   Vavrusova, Livia ^e   Chaban, Oleg ^f   Gruget, Céline ^g   Olivier, Valérie ^g   Picarel Blanchot, Françoise ^g   de Bodinat, Christian ^g  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b Mehilainen Oy   (Finland)

^c INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

^d Laboratory of Immunochemistry   (Russian Federation)

^e Private dental office DEIMPERIO sro   (Slovakia)

^f BOGOMOLETS NATIONAL MEDICAL UNIVERSITY   (Ukraine)

^g IRIS Institut de Recherches Internationales Servier   (France)

Author keywords

Agomelatine; Generalized anxiety disorder; Placebo

Indexed keywords

AGOMELATINE; PLACEBO; ACETAMIDE DERIVATIVE; HYPNOTIC SEDATIVE AGENT;

ADULT; ARTHRALGIA; ARTICLE; BACKACHE; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FINLAND; GENERALIZED ANXIETY DISORDER; HAMILTON ANXIETY SCALE; HEADACHE; HUMAN; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; PLACEBO EFFECT; POLAND; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHINOPHARYNGITIS; RUSSIAN FEDERATION; SINUSITIS; SLOVAKIA; SOMNOLENCE; UKRAINE; UNSPECIFIED SIDE EFFECT; XEROSTOMIA; ANXIETY DISORDER; CLINICAL TRIAL; DOSE RESPONSE; FOLLOW UP; INTERNATIONAL COOPERATION; MIDDLE AGED; OUTPATIENT; PSYCHOLOGICAL RATING SCALE; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ACETAMIDES; ADULT; ANXIETY DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPNOTICS AND SEDATIVES; INTERNATIONAL COOPERATION; MALE; MIDDLE AGED; OUTPATIENTS; PSYCHIATRIC STATUS RATING SCALES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 85014763688     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2017.02.007     Document Type: Article

References (34)

1. Allgulander, C., Hackett, D., Salinas, E., 2001. Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. Br. J. Psychiatry 179, 15–22. Baldwin, D.S., Huusom, A.K., Maehlum, E., 2006. Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study. Br. J. Psychiatry 189, 264–272. Bandelow, B., Lichte, T., Rudolf, S., Wiltink, J., Beutel, M.E., The diagnosis of and treatment recommendations for anxiety disorders. Dtsch. Arztebl. Int. 111 (2014), 473–480.
2. de Bodinat, C., Guardiola-Lemaitre, B., Mocaer, E., Renard, P., Munoz, C., Millan, M.J., Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat. Rev. Drug Discov. 9 (2010), 628–642.
3. Dechartres, A., Boutron, I., Trinquart, L., Charles, P., Ravaud, P., Single-center trials show larger treatment effects than multicenter trials: evidence from a meta-epidemiologic study. Ann. Intern. Med. 155 (2011), 39–51.
4. Fava, M., Rush, A.J., Alpert, J.E., Carmin, C.N., Balasubramani, G.K., Wisniewski, S.R., Trivedi, M.H., Biggs, M.M., Shores-Wilson, K., What clinical and symptom features and comorbid disorders characterize outpatients with anxious major depressive disorder: a replication and extension. Can. J. Psychiatry 51 (2006), 823–835.
5. Guardiola-Lemaitre, B., Bodinat, C., Delagrange, P., Millan, M.J., Munoz, C., Mocaer, E., Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties. Br. J. Pharmacol., 2014.
6. Guy, W., 1976. ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education and Welfare publication ADM 76-338. National Institute of Mental Health, Rockville MD, pp. 217–222.
7. Hale, A., Marcelo-Corral, R., Mencacci, C., Saiz Ruiz, J., Albarran Severo, C., Gentil, V., Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study. Int. Clin. Psychopharmacol. 25 (2010), 305–314.
8. Hamilton, M., The assessment of anxiety states by rating. Br. J. Med. Psychol. 32 (1959), 50–55.
9. Hoertel, N., Le, S.Y., Blanco, C., Lavaud, P., Dubertret, C., Generalizability of clinical trial results for generalized anxiety disorder to community samples. Depress. Anxiety 29 (2012), 614–620.
10. Hoffman, D.L., Dukes, E.M., Wittchen, H.U., Human and economic burden of generalized anxiety disorder. Depress. Anxiety 25 (2008), 72–90.
11. ICH E9, 1999. ICH Harmonised Tripartite Guideline. Statistical principles for clinical trials. International Conference on Harmonisation E9 Expert Working Group. Stat. Med. 18, pp. 1905–1942.
12. Kapczinski, F., Lima, M.S., Souza, J.S., Schmitt, R., Antidepressants for generalized anxiety disorder. Cochrane. Database Syst. Rev., 2003 (CD003592).
13. Kasper, S., Hajak, G., Wulff, K., Hoogendijk, W.J., Montejo, A.L., Smeraldi, E., Rybakowski, J.K., Quera-Salva, M.A., Wirz-Justice, A.M., Picarel-Blanchot, F., Bayle, F.J., Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline. J. Clin. Psychiatry 71 (2010), 109–120.
14. Kennedy, S.H., Emsley, R., Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur. Neuropsychopharmacol. 16 (2006), 93–100.
15. Kennedy, S.H., Avedisova, A., Gimenez-Montesinos, N., Belaidi, C., de Bodinat, C., A placebo-controlled study of three agomelatine dose regimens (10 mg, 25 mg, 25–50 mg) in patients with major depressive disorder. Eur. Neuropsychopharmacol. 24 (2014), 553–563.
16. Kennedy, S.H., Avedisova, A., Belaidi, C., Picarel-Blanchot, F., de Bodinat, C., Sustained efficacy of agomelatine 10 mg, 25 mg, and 25–50 mg on depressive symptoms and functional outcomes in patients with major depressive disorder.A placebo-controlled study over 6 months. Eur. Neuropsychopharmacol. 26 (2016), 378–389.
17. Koponen, H., Allgulander, C., Erickson, J., Dunayevich, E., Pritchett, Y., Detke, M.J., Ball, S.G., Russell, J.M., 2007. Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians. Prim. Care Companion. J. Clin. Psychiatry 9, 100–107. Lemoine, P., Guilleminault, C., Alvarez, E., Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J. Clin. Psychiatry 68 (2007), 1723–1732.
18. Loo, H., Hale, A., D׳haenen, H., Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT2C antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int. Clin. Psychopharmacol. 17 (2002), 239–247.
19. Millan, M.J., Brocco, M., Gobert, A., Dekeyne, A., 2005. Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade. Psychopharmacology (Berlin) 177, 448–458. Montgomery, S.A., Asberg, M., A new depression scale designed to be sensitive to change. Br. J. Psychiatry 134 (1979), 382–389.
20. Olié, J.P., Kasper, S., Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int. J. Neuropsychopharmacol. 10 (2007), 661–673.
21. Papp, M., Litwa, E., Gruca, P., Mocaer, E., 2006. Anxiolytic-like activity of agomelatine and melatonin in three animal models of anxiety. Behav. Pharmacol. 17, 9–18. Pecenak, J., Novotny, V., Agomelatine as monotherapy for major depression: an outpatient, open-label study. Neuropsychiatr. Dis. Treat. 9 (2013), 1595–1604.
22. Perlemuter, G., Cacoub, P., Valla, D., Guyader, D., Saba, B., Batailler, C., Moore, K., Characterisation of Agomelatine-Induced Increase in Liver Enzymes: frequency and Risk Factors Determined from a Pooled Analysis of 7605 Treated Patients. CNS Drugs 30 (2016), 877–888.
23. Rickels, K., Schweizer, E., The spectrum of generalised anxiety in clinical practice: the role of short-term, intermittent treatment. Br. J. Psychiatry Suppl., 1998, 49–54.
24. Servier Laboratories, 2015. Summary of product characteristics: Valdoxan.
25. Sheehan, D.V., Harnett-Sheehan, K., Raj, B.A., The measurement of disability. Int. Clin. Psychopharmacol. 11:Suppl 3 (1996), S89–S95.
26. Sheehan, D.V., Lecrubier, Y., Sheehan, K.H., Amorim, P., Janavs, J., Weiller, E., Hergueta, T., Baker, R., Dunbar, G.C., The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 59:Suppl 20 (1998), S22–S33.
27. Sheehan, K.H., Sheehan, D.V., Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability Scale. Int. Clin. Psychopharmacol. 23 (2008), 70–83.
28. Stein, D.J., Hollander, E., 2002. Anxiety Disorders Comorbid with Depression: Social Anxiety Disorder, Post-Traumatic Stress Disorder, Generalized Anxiety Disorder and Obsessive-Compulsive Disorder. Martin Dunitz, London.
29. Stein, D.J., Ahokas, A.A., de Bodinat, C., Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J. Clin. Psychopharmacol. 28 (2008), 561–566.
30. Stein, D.J., Ahokas, A.A., Albarran Severo, C., Olivier, V., Allgulander, C., Agomelatine prevents relapse in generalised anxiety disorder: a 6-month placebo-controlled discontinuation study. J. Clin. Psychiatry 73 (2012), 1002–1008.
31. Stein, D.J., Ahokas, A., Marquez, M.S., Hoschl, C., Oh, K.S., Jarema, M., Avedisova, A.S., Albarran, C., Olivier, V., Agomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study. J. Clin. Psychiatry 75 (2014), 362–368.
32. Stein, D.J., Picarel-Blanchot, F., Kennedy, S.H., 2013. Efficacy of the novel antidepressant agomelatine on anxiety symptoms in major depression.
33. Wittchen, H.U., Jacobi, F., Rehm, J., Gustavsson, A., Svensson, M., Jonsson, B., Olesen, J., Allgulander, C., Alonso, J., Faravelli, C., Fratiglioni, L., Jennum, P., Lieb, R., Maercker, A., van, O.J., Preisig, M., Salvador-Carulla, L., Simon, R., Steinhausen, H.C., The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur. Neuropsychopharmacol. 21 (2011), 655–679.
34. Zigmond, A.S., Snaith, R.P., The hospital anxiety and depression scale. Acta Psychiatr. Scand. 67 (1983), 361–370.